Scarica l'app Stockscreener
0.2022
0.88%
-0.0018
Precedente Chiudi:
$0.204
Aprire:
$0.2015
Volume 24 ore:
63,711
Relative Volume:
0.23
Capitalizzazione di mercato:
$7.91M
Reddito:
$20.27M
Utile/perdita netta:
$-63.80M
Rapporto P/E:
-0.133
EPS:
-1.52
Flusso di cassa netto:
$-68.35M
1 W Prestazione:
-4.58%
1M Prestazione:
-38.73%
6M Prestazione:
-79.98%
1 anno Prestazione:
-87.89%
Intervallo 1D:
$0.1937
$0.2043
Intervallo di 1 settimana:
$0.1937
$0.2296
Portata 52W:
$0.1601
$1.90
Carisma Therapeutics Inc Stock (CARM) Company Profile
Nome
Carisma Therapeutics Inc
Settore
Industria
Telefono
(267) 491-6422
Indirizzo
3675 MARKET STREET, PHILADELPHIA
Confronta CARM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CARM
Carisma Therapeutics Inc
|
0.2022 | 7.91M | 20.27M | -63.80M | -68.35M | -1.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.04 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.12 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
628.63 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.46 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
248.64 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-12-10 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-04-11 | Iniziato | BTIG Research | Buy |
| 2023-10-03 | Iniziato | CapitalOne | Overweight |
| 2023-07-06 | Iniziato | Evercore ISI | Outperform |
| 2023-05-31 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-05-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-04-14 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Carisma Therapeutics Inc Borsa (CARM) Ultime notizie
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Carisma Therapeutics to Present at Upcoming Conferences - Seeking Alpha
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Average Rating of “Hold” by Analysts - Defense World
Sagimet Biosciences (NASDAQ:SGMT) and Carisma Therapeutics (NASDAQ:CARM) Head-To-Head Review - Defense World
Philly weekly roundup: Carisma Therapeutics layoffs; PPA's AI ticketing; HiveBio's first cohort - Technical.ly
Carisma Therapeutics Inc’s Market Journey: Closing Weak at 0.19, Down -0.26 - DWinneX
CARISMA THERAPEUTICS Earnings Preview: Recent $CARM Insider Trading, Hedge Fund Activity, and More - Nasdaq
Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan - MSN
Philly’s Carisma Therapeutics slashed its workforce to 6 from 46 for sale or wind down - MSN
Carisma Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Carisma Therapeutics (NASDAQ:CARM) Price Target Lowered to $1.00 at D. Boral Capital - Defense World
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Carisma Therapeutics to Present at AASLD 2024 on Liver Fibrosis Treatment - MSN
Carisma winds down operations, lays off 95% of remaining staff - Fierce Biotech
Penn spinout Carisma Therapeutics lays off 84% of its staff, explores possible sale - The Business Journals
Carisma Therapeutics Provides Corporate Updates - Citizen Tribune
Carisma Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Carisma Therapeutics Board Approves Revised Operating Plan; Reduces Workforce - MarketScreener
Carisma Therapeutics Inc. SEC 10-K Report - TradingView
Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry - simplywall.st
Carisma Therapeutics (CARM) to Release Earnings on Monday - Defense World
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of “Hold” from Analysts - Defense World
Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annua - GuruFocus.com
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Michael Klichinsky to Speak at H.C. Wainwright Cell Therapy Virtual Conference - MSN
Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 - Quantisnow
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Quantisnow
Carisma Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Conference - MSN
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference - Quantisnow
Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update - Defense World
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Biliary Tract Cancer Market Poised for Significant Growth from - openPR.com
BTIG Downgrades Carisma Therapeutics (CARM) - MSN
Evercore ISI Group Downgrades Carisma Therapeutics (CARM) - MSN
Barclays PLC Has $539,000 Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World
Carisma Therapeutics Inc Azioni (CARM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.36%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):